Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY: Comparison of Immunosuppressive Regimens in Renal Transplantation
NCT00231764Phase 4Completed
- Start
- Nov 2002
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of daclizumab in kidney transplant rejection (4 arms). Primary endpoint: Glomerular Filtration Rate at 12 months. Started Nov 2002; status: completed.
02
Drugs
daclizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00231764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231764.